News
It began in 2020 with a coordinated push to generate public backlash to lockdowns. The ultimate aim was restoring normalcy, ending a politically and economically inconvenient crisis. Over time, ...
Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter ...
1h
Zacks Investment Research on MSNBiotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...
Explore more
The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...
Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results